Prostate cancer is the most common cancer in men accounting for around 24% of all male cancers in United Kingdom. The role of chemotherapy in the neoadjuvant and adjuvant setting is still unclear despite considerable progress in this area. Chemotherapy for advanced prostate cancer has become the standard of care, however options of treatment following taxotere failure are still limited. This review summarizes recent advances in chemotherapy treatment options for early as well as advanced prostate cancer.
Introduction
Prostate cancer remains the most common cancer in men accounting for around 24% of all male cancers in United Kingdom. The approach to organ-confined disease is gradually changing with the emphasis on avoiding unnecessary treatment 'active surveillance' and the development of local therapies as alternatives to external beam radiotherapy and radical prostatectomy. The role of chemotherapy in the neoadjuvant and adjuvant setting to accompany any of these options is still unclear despite considerable progress in other solid tumours in the same context. The optimism for progress in treating organconfined prostate cancer still has to be tempered by the lack of effective options for individuals with hormone refractory prostate cancer (HRPC). In the past few years taxotere chemotherapy has become a standard of care for HRPC following the landmark TAX 327 and SWOG 9916 studies that showed that chemotherapy can offer a survival advantage and control cancer-related symptoms.
1,2 Beyond taxotere, the patient pathway is very uncertain as no current second-line chemotherapeutic agent alters the natural history of the disease. There is, therefore, a considerable unmet need for a large patient population worldwide, and this is being actively addressed by the development of studies with novel chemotherapies increasingly in combination with targeted therapies.
Neoadjuvant chemotherapy
Chemotherapy has been tested in the neoadjuvant context prior to radical prostatectomy. Such studies are difficult to evaluate in view of relatively favourable prognostic group of patients targeted, end points used prostate-specific antigen (PSA), progression-free survival (PFS) rather than overall survival (OS) and longevity of the studies. Fears of alteration of histological features particularly at resection margins in the post-resection tumour have so far been unfounded. The studies invariably extrapolate the treatment approach from positive findings of metastatic studies. Of the agents evaluated, taxotere was well tolerated and resulted in 81% of patients (with a median follow-up of 26.5 months) showing no recurrence in PSA post-prostatectomy. 3 Estramustine alone, as well as in combination with taxotere may also be active in this setting with 71-84% of patients achieving a biochemical disease-free survival of 9-23 months. [4] [5] [6] A large randomized phase III study of radical prostatectomy alone versus taxotere and androgen deprivation before radical prostatectomy (Cancer and Leukemia Group B-CALGB 90203) for high-risk patients is currently ongoing (www.calgb.org/).
Adjuvant chemotherapy
Adjuvant chemotherapy is the standard of care after radical surgery in most common epithelial cancers such as breast, bowel, lung and ovarian cancer, where it offers a survival advantage but is still associated with acceptable toxicity. The difference in the prostate cancer context has been the lack of efficacy of a large number of chemotherapies in the metastatic setting, unlike in breast and gastrointestinal cancers. At the same time, patients at 'high risk' with presumed micrometastatic disease may be easily identified and targeted for new studies.
Previously, the National Prostate Cancer Project compared cyclophosphamide or estramustine with observation after radical prostatectomy or radiotherapy and found that the estramustine-treated group had a significantly longer PFS than the other groups. 7 Adjuvant weekly taxotere in patients with high-risk prostate cancer after radical prostatectomy 8 has been reported recently. At a median follow-up of 28 months (range 10.5-38.5), the median PFS of 15.7 months was longer than the predicted 10-month median PFS for a matched population. Two large randomized phase III studies are currently under way: the SWOG 9921 trial compares mitoxantrone/prednisolone in addition to 2 years of hormone treatment versus hormone treatment alone (www.swog.org). The TAX 3501 study compares taxotere in a four-arm study with immediate versus delayed hormone deprivation therapy.
Chemotherapy for metastatic disease
Despite the advent of molecular-based therapy and antiangiogenic strategies, there has been intense activity in evaluating new chemotherapeutic agents in the metastatic setting. Satraplatin is a third generation platinum compound, structurally similar to cisplatin and orally bioavailable. 9 Phase II data showed promising results with median survival (MS) of 16.7 months, and median PFS of 7.7 months. 10 On the basis of the results of this trial, a large phase III trial was organized by European Organisation for Research and Treatment of Cancer. Unfortunately, due to the problems with the sponsoring company the trial recruitment was terminated after only 50 out of 380 patients were enrolled. 11 The analysis of the 50 patients showed the median PFS twice as long on the satraplatin arm (5.2 versus 2.6 months) and there was a trend towards improved OS, 14.9 versus 11.9 months. Two further satraplatin studies were terminated early (CA142-029 and CA142-026) and there is no data analysis available. Satraplatin in second-line chemotherapy setting, after taxotere failure, was investigated in a SPARC (SatraPlatin Against Refractory Cancers) trial. The multicentre phase III study was reported in 2007. 12 A total of 950 patients were accrued. Patients in the satraplatin arm had a 31% reduction in the risk of PFS events compared to placebo (HR: 0.69; confidence interval, CI: 0.5-0.8), objective tumour response (7 versus 1%) and pain response (24 versus 14%). The commonest side effect was myelosupression, although grade 4 toxicity was uncommon (4%). Unfortunately, the trial did not achieve the end point of OS. The MS was 61.3 weeks for the satraplatin arm compared to 61.4 weeks for the control group and the hazard ratio was 0.97 (95% CI: 0.83, 1.13).
A novel class of tubule-polymerising agents, epothilones, has been tested in metastatic HRPC. The drugs act by stabilising cellular microtubules inducing mitotic arrest, in a similar way to taxanes. They have been shown to be effective in taxane-sensitive and taxaneresistant tumour cell lines. 13 Epothilones were tested as first-line treatment for HRPC as well as second-line chemotherapy. A phase II study of ixabepilone, by SouthWest Oncology Group showed median PFS of 6 months, MS of 18 months and 39% of patients had a true (X50%, sustained over two readings 4 weeks apart) PSA response.
14 Ixabepilone in combination with estramustine showed a 48% objective radiological response in the combination arm versus 32% with ixabepilone alone. 15 The PSA response was 69 versus 48% and time to PSA progression was 5.2 versus 4.4 months, respectively. Ixabepilone following taxotere treatment failure was compared to mitoxantrone. 16 A PSA response was seen in 20% of patients treated with mitoxantrone versus 17% on the ixabepilone arm; the MS was 13 and 12 months, respectively. Epothilone B (patupilone) is also active in patients who had previous taxane therapy and associated with a 25% PSA response. 17 Several novel-targeted agents have now been used in HRPC in combination with chemotherapy or as single agents. One of the most active drugs is atrasentan, an endothelin-A receptor antagonist. Endothelin-1 promotes tumour growth and progression and may be involved in the development of bone metastases. 18 Atrasentan has been subjected to a number of studies: a meta-analysis of the data showed a significantly longer time to disease progression, longer time to bone pain and longer time to biochemical progression. 19 The eventual utility of atresentan may be in combination with other agents such as docetaxel or other chemotherapy agents.
Angiogenesis inhibitors such as bevacizumab have been tested in HRPC in combination with taxotere and estramustine. The CALGB 90006 trial showed very high responses with 81% of patients achieving a PSA response, as compared to 68% in patients treated with taxotere and estramustine alone. 20 In this study, the overall MS was 21 versus 19 months, respectively. A large phase III study CALGB 90401 of taxotere and prednisolone with and without bevacizumab is currently ongoing.
Thalidomide as an anti-angiogenic and immunostimulatory agent has undergone phase II evaluation in prostate cancer as a single agent. A combination of thalidomide and taxotere resulted in 53% PSA response and increased median time to disease progression of 5.9 months. 21 The addition of bevacizumab to this combination resulted in not only higher responses but also high toxicity. 22 A PSA response was reported in 87% of patients but 12.8% had febrile neutropenia and several patients had significant toxicities such as syncope, grade 3 bleeding, colon perforation or fistula formation and thrombosis.
Gefitinib, an orally active epidermal growth factor receptor tyrosine kinase inhibitor is reported to be moderately active in HRPC as a single agent, however the comparison with placebo showed no difference in time to progression, progression rate or OS. 23 In combination with prednisolone it appears to achieve PSA control and prolongs patients survival. 24 A total of 82 patients were enrolled and median time to death was 26.5 months as compared to 20.5 months in placebo group.
Vitamin D analogues show anti-tumour activity in several prostate cancer models. 25 The mode of action is by inhibition of proliferation and cell-cycle arrest, induction of apoptosis and reduction of invasiveness and angiogenesis. [26] [27] [28] Phase II on data on 26 patients of combination of DN-101 with taxotere in patients with HRPC previously treated with taxotere showed that it is a well-tolerated and active combination. 29 A randomized phase III study of high-dose calcitriol plus taxotere versus placebo plus taxotere (ASCENT study) confirmed the above results. 30 Overall PSA response rates were 63%
Prostate cancer chemotherapy A Michael et al (DN-101) and 52% (placebo). Grade 3/4 adverse events were frequent-58%, but the placebo group recorded 70% rate. The analysis showed a trend towards improvement in survival but survival was not a primary end point. The ASCENT II study comparing survival with weekly or every 3 weeks doses of docetaxel in combination with DN-101 with standard docetaxel and prednisone was closed due to safety issues and imbalance of deaths between the two treatment arms.
Other new drugs that are currently in early phase trials for HRPC include Halichondron B Analog-E7389, an antimicrotubule agent, and Ispinesib (SB-715992) acting on mitotic protein subsequently leading to cellcycle arrest and cell death.
Various chemotherapy combinations have been tried as a second-line treatment but none of the options have had any impact on OS. Vinorelbine and estramustine demonstrated activity and longer median OS, the numbers of patients treated however were very small. 31 Taxotere in combintaion with carboplatin is also active with PSA responses seen in 18% of patients. 32 Chemotherapy with taxotere is now a standard approach for HRPC. However, significant numbers of patients progress and are fit for further lines of treatment. No single agent has so far made a significant impact following taxotere failure but numerous further single agent and combination studies are ongoing. The development of molecular or 'targeted' therapy called into the question the future of more traditional chemotherapeutic strategies. Rather than discarding cytotoxic approaches it is most likely that their maximum utility will be in combination with targeted therapy.
